Program Introduction Technologies Used to Produce Therapeutic mAbs Molecular Structures of Biologic Drugs Used to Treat Psoriasis Biologics Consequences of ADAs Consequences of ADAs Biologics Types of ADAs ID: 649777
Download Presentation The PPT/PDF document "Monoclonal Antibodies and Immunogenicity..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?Slide2
Program Introduction Slide3
Technologies Used to Produce Therapeutic mAbsSlide4
Molecular Structures of Biologic Drugs Used to Treat PsoriasisSlide5
Biologics: Consequences of ADAsSlide6
Consequences of
ADAsSlide7
Biologics: Types of ADAsSlide8
Relationship of Developing ADAs to Type of mAbSlide9
Immunogenicity of IL-17a and IL-12/23 Antibodies Are Low vs Other mAbsSlide10
Ixekizumab TE-ADAs Reported in the Phase 3 UNCOVER TrialsSlide11
Relevance of ADAs for Treatment Strategies With Human or Chimeric AntibodiesSlide12
Concluding RemarksSlide13
Abbreviations